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Abstract
The aim of this Global Allergy and Asthma European Network (GA2LEN) consen-
sus report is to provide recommendations for patient-reported outcomes (PROs)
evaluation in clinical trials for allergic diseases, which constitute a global health
problem in terms of physical, psychological economic and social impact. During the
last 40 years, PROs have gained large consideration and use in the scientiﬁc com-
munity, to gain a better understanding of patients’ subjective assessment with
respect to elements concerning their health condition. They include all health-related
reports coming from the patient, without involvement or interpretation by physician
or others. PROs assessment should be performed by validated tools (disease-speciﬁc
tools when available or generic ones) selected taking into account the aim of the
study, the expected intervention effects and the determinant and confounding fac-
tors or patient-related factors which could inﬂuence PROs. Moreover, each tool
should be used exclusively in the patient population following the authors’ indica-
tions without modiﬁcation and performing a cross-cultural validation if the tool
must be used in a language that differs from the original. The result analysis also
suggests that the relevance of PROs results in any interventional study should
include a pre–post assessment providing information concerning statistical differ-
ences within or among groups, rates of response for the PROs and a minimal
important difference for the population. The report underlines the importance of
further investigation on some topics, such as the quality assessment of existing
PROs tools, the deﬁnition of inclusion and exclusion criteria and a more extensive
evaluation of the correlation between PROs, besides health-related quality of life,
and clinical data.
Abbreviations
EMEA, European Medicines Agency; FDA, United States (US) Food and Drug Administration; HRLQ/HRQoL, health-related quality of life;
MID, minimal important difference; PROs, patient-reported outcomes.
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Concept and definition of health-related quality of life
(HRQoL or HRQL) and patient-reported outcomes
(PROs)
During the last 40 years, clinicians and researchers have recog-
nized the importance of considering the subjective dimension
of diseases to have a more global and coherent vision about
the patient and the effects of the whole health-care process.
This development was driven by the clinical necessity to go
beyond the limits of ‘disease-centred medicine’ and reaches the
wider and more global perspective of ‘patient-centred medi-
cine’. As mentioned in the WHO Health Report (2008):
‘people-centredness is not a luxury, it is a necessity’ (1). People
do not think about health only in terms of targets for disease
control programmes, but also in terms of what they perceive,
according to their beliefs and their particular situation in life.
There are several deﬁnitions of this impact on subjective
experience. Some researchers are prone to emphasize health
aspects (HRQL or HRQoL); however, nowadays, the expres-
sion PROs seems to be more used, because it focuses on the
interest in the whole host of outcomes. Anyway, it cannot be
forgotten that in a nonclinical setting, PROs could mean Per-
son-Reported Outcomes (2). PROs include all health-related
reports coming from the patient, without involvement or
interpretation by physician or others, such as symptoms,
HRQL, illness perception, satisfaction or adherence to treat-
ment (3). Health Outcome Assessment has also been proposed
to avoid specifying the respondent (1).
Patient-reported outcomes have recently gained large con-
sideration and use in the scientiﬁc community, with the aim
of gaining a better understanding of patient’s subjective
assessment with respect to elements concerning their health
condition (4). PROs focus the attention only on the patient,
because she or he is the only person authorized to provide
information about the personal experience of the disease,
treatment and care. Therefore, PROs provide information
unavailable from other sources, such as laboratory measures,
caregiver reports or physician’s judgements that is crucial for
predicting health outcomes and for establishing health policy.
Patient-reported outcomes must be evaluated by validated
tools exploring the patients’ perceptions related to outcome.
Speciﬁcally developed instruments such as questionnaires,
composite scores and visual analogue scale (VAS) are neces-
sary to understand how the patients perceive and evaluate
their disease experience and therapy effects (4).
Patient-reported outcomes are affected by disease-related
aspects (e.g. severity, chronicity, treatment schedule) and
patient-related factors (e.g. alexithymia, stress, coping, mood).
Moreover, each PRO can be inﬂuenced by other PROs – e.g.
the level of asthma control may inﬂuence the HRQoL (5).
Patient-reported outcomes evaluation is relevant in clinical,
research, routine medical practice and regulatory processes.
The United States (US) Food and Drug Administration
(FDA) (6) and the European Medicines Agency (EMEA) (7)
have recently focused on PROs evaluation. EMEA suggests
that especially in nonlife-threatening chronic conditions,
when two drugs show similar efﬁcacy, the patient’s evalua-
tion provided by PROs could be useful in deﬁning the drug
to be recommended. Between 1999 and 2003, 34% of all eval-
uations submitted to EMEA for the registration of a new
drug, also for the use in the paediatric age (8), included data
on HRQL and other PROs, and this rate has been constantly
increasing ever since (9).
Recently, Scoggins and Patrick (10) showed that 14% of
all international trials registered between September 2004 and
September 2007 included a PRO as an outcome.
PROs in allergic diseases
Allergic diseases constitute a global health problem: they
appear to be increasing in prevalence and account for signiﬁ-
cant morbidity and socioeconomic costs (11). On the basis of
this evidence, they have been deﬁned as one of the epidemics
of the 21st century (12).
Health-related quality of life impairment has been well
established for rhinitis, asthma (13), atopic dermatitis (14),
urticaria (15) and food (16). Allergic diseases exert a consid-
erable economic and social impact not only because they are
highly prevalent in many parts of world but also because
their presence interferes signiﬁcantly with many aspects of
daily life as a result of physical discomfort and impairment
along with emotional distress (17, 18).
A growing number of clinical trials for allergic diseases
include PROs assessment (19–25). The aim of this GA2LEN
consensus report is to provide recommendations for PROs
evaluation in clinical trials for allergic diseases.
PROs as primary, co-primary or secondary outcome
Assessment of PROs is rarely the primary but rather a sec-
ondary outcome in clinical trials (26–28). In this case, the
trials sample size is calculated based on the primary outcome,
and the results for PROs as a secondary outcome should be
carefully evaluated in terms of the relationship between the
PROs and the sample size.
The development of clinical trials in which PROs are the
primary or co-primary (29) outcome is recommended because
appropriate tools are available.
Selection of instruments for PROs assessment
l The assessment of PROs should be performed by vali-
dated tools selected according to the aim of the study.
s In clinical trials, disease-speciﬁc tools (whenever avail-
able) should be preferred over generic tools. Speciﬁc
questionnaires are more sensitive than generic ones
when measuring changes in the same population
before and after an intervention. When a speciﬁc tool
is not available, its development is recommended. A
PROs tool can be considered validated if the valida-
tion procedure has been followed (Appendix S1), and
if this procedure and its results are published in a
peer-reviewed journal.
s However, because allergic disease can affect more than
one organ simultaneously, some tools can be used for
the assessment of different clinical features (30).
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s For HRQoL assessment, ‘generic questionnaires’
should be used when a speciﬁc tool is not available or
for a comparison between two different populations of
patients [e.g. rhinitis vs asthma patients (13)] or between
patients and healthy subjects (31). In this case, ‘disease-
or symptom-speciﬁc questionnaires’ may be used in
association with generic tools or alone (32).
l In trials that assess speciﬁc effects of an intervention (e.g.
effect on sleep, on pain…), the choice of a speciﬁc PROs
tool, whenever available, should be made taking into
account the expected intervention effects.
l When PROs evaluation is part of a trial, determinant and
confounding factors inﬂuencing PROs should be
considered.
l A Ga2len registry of the validated tools is available on its
Web site (http://www.ga2len.net). In the registry, the
researchers can ﬁnd data useful for the choice of the suit-
able tool according to the aim of the study (Table 1).
l All PROs and patient-related factors inﬂuencing PROs
should be assessed using validated tools if available
(Appendix S2).
l If symptoms are assessed using symptom scores, informa-
tion about the validity, reliability and responsiveness of
the tool should be provided when available (33).
l The VAS is a technique used to measure subjective
phenomena (34). It is considered a robust, sensitive and
reproducible method for symptom assessment (35). How-
ever, the interaction between the behavioural tendencies
of patients and the physical characteristics of the scale
causes it to be nonlinear and prone to response bias (35–
38). For this reason, an assessment is subjective, and these
scales are more valuable when looking at changes within
individuals and are less interesting for comparing across a
group of individuals at 1 time point (15, 34, 38).
l The use of composite-validated clinical assessment tools –
e.g. Asthma Control Test (39) and Asthma Control Ques-
tionnaire (40) is useful in clinical trials and real life assess-
ment. The development of such kind of tools in all
allergic disorders is encouraged. However, tools that
include clinical/functional measures (e.g. peak expiratory
ﬂow) beside PROs (e.g. symptoms) are not fully patient
centred (41).
l The administration time of an instrument in a clinical
trial should take into consideration the time frame it
refers to (e.g. instruments that take into consideration
what happened in the last 4 weeks are not suitable for
short-term trials).
l The methods of trials should include the reason(s) for
choosing the PROs instrument selected.
Patient-reported bias
In open-labelled trials, patient-reporting bias is troublesome,
because the most obvious setting in which bias may be intro-
duced by the patient is self-reported assessment, which repre-
sents the basis of PROs. Many examples can be listed such
as pain scales and quality of life (42). Some of the most plau-
sible factors inducing biases are apprehension bias (e.g.
increased blood pressure when the subject is apprehensive),
obsequiousness bias (subjects may want to please investiga-
tor) and expectation bias (43).
Sample size and population in PROs assessment
l At present, information on the minimal number of
patients to be involved in a clinical trial is not available
for each PROs tool. A power calculation should be based
on tools’ features and the estimation of the drop-out rate.
l Each tool is to be used exclusively in the patient popula-
tion for which it was developed and validated (e.g. use of
adults’ tools in adolescents is not correct).
Correct administration of tools
l The use of PROs tools should follow the authors’ indica-
tions (e.g. no medical or caregiver ﬁlling-in, no phone
interview, no mail delivery if not indicated).
l The tool cannot be modiﬁed (items, instructions and
response items), and no item can be added or removed.
l When using a tool, it should be checked whether its use is
regulated or limited by patent copyright or commercial
fees.
l A PROs tool can only be used in a language that dif-
fers from the original after translation and back-transla-
tion, and a cross-cultural validation is performed
(Appendix S3). A simple translation of the tool is not
sufﬁcient.
PROs result analysis
l The used tool should be analysed according to its
structure (e.g. factor scores, global score). The analysis
Table 1 Health-related quality of life and patient-reported out-
comes Ga2len registry
Name of the tool
Acronym
Author
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of isolated items or item combinations different from
the factors deﬁned in the validation process is not
allowed.
l Each score must be calculated according to authors’
instructions.
l Complete results (i.e. positive) scores must be reported.
The negative, no change and the number of missing data
and response rates should be provided.
l It is not allowed to extend the results from one popula-
tion to other patients populations (e.g. different age
group/demographical data, disease severity, duration of
treatment, etc.).
l Patient-reported outcomes analyses and reporting in clini-
cal trials should take into account and/or be adjusted for
confounding/inﬂuencing factors. These factors should be
declared in advance.
l The relevance of PROs results in any interventional
study should include a pre–post assessment. The results
should provide information concerning statistical differ-
ences within groups or among groups, rates of response
for the PROs outcome and a minimal important differ-
ence (MID) (44) for the population. This is relevant,
because a single MID value for a PRO instrument does
not exist across all patient samples. The MID may be
different according to population and context, and no
single MID may be valid for all study applications
which refer to a PROs tool (45). Because the sample size
of the study can be calculated only through study
power, type I error and the expected effects, and these
elements can be assumed only by past experiences, the
use of MID calculated on previous studies is recom-
mended.
Unexplored areas and suggested topics of
investigation
l Existing tool should undergo widespread cross-cultural
validation to allow for their use in large multicentre inter-
national trials. New tools that are developed should be
simultaneously validated in different languages (46).
l Minimal important differences for speciﬁc populations
and PROs tools should be established.
l Further quality assessment of existing PROs tools is
needed.
l The development of clinical trials in which PROs are the
primary outcome is recommended.
l The correlation among PROs, patient factors inﬂuencing
PROs as well as the correlation among PROs themselves
should be explored.
l The impact of doctor/patient communication on PROs
needs investigations, because currently patients’ and doc-
tors’ viewpoints on the quality of their relationship differ
signiﬁcantly (47).
l Instruments for symptoms assessment should be opti-
mized through a validation process.
l Patients inﬂuencing PROs should be investigated as fac-
tors to be taken into account in inclusion and exclusion
criteria deﬁnition.
l A more extensive evaluation of the correlation between
PROs, besides HRQoL, and clinical data is needed.
l For the paediatric population, the extensive use of PROs
and the development in the paediatric investigation plans
(PIPs) should be strongly encouraged. PIPs were intro-
duced by the European Commission to help ensure that
medicines for children are included in the mainstream
drug development process in Europe, rather than as an
optional extra (48).
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